BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 15, 2008
View Archived Issues
Partial alphavbeta6 inhibition prevents lung fibrosis without increasing inflammation
Read More
Potent analgesic activity of ABT-102 in preclinical studies
Read More
Intranasal versus i.v. orexin-A in memory enhancement of sleep-deprived monkeys
Read More
LFB and GTC enter collaboration for coagulation factor IX program for type B hemophilia
Read More
Cadence reports topline results from the 301 and 302 phase III clinical trials of Acetavance
Read More
Starpharma expands phase I trial of VivaGel and completes enrollment in herpes study
Read More
Hemispherx submits responses to FDA questions on NDA for Ampligen for CFS
Read More
Nucleonics initiates phase I human safety study of NUC-B1000 for chronic HBV infection
Read More
The immunosuppressant FTY-720 shows promise in hematological cancer
Read More
Aviation Upgrade Technologies changes its name to OncoVista Innovative Therapies
Read More
Adventrx reports ANX-530 safety data and plans NDA submission
Read More
Diamyd submits IND for phase I novel chronic pain therapy trial
Read More
FDA extends review of Genasense NDA appeal
Read More
Pharmion submits E.U. MAA for Vidaza in patients with MDS
Read More
Protherics and Advancell enroll first patient in B-cell lymphocytic leukemia study
Read More
Novel psychopharmacologic drugs described
Read More
Ube and Santen patent claims novel agents for glaucoma
Read More
JAK3/CDK4 inhibitors emerge from Novartis R&D
Read More
Tysabri approved in U.S. for moderate to severe Crohn's disease
Read More
Novo Nordisk discontinues development of AERx inhaled insulin
Read More
Wellcome Trust awards GBP 3.5 million to Novacta to target Clostridium difficile
Read More
Alder completes USD 40M series C financing and advances development of ALD-518
Read More
CollaGenex initiates phase II clinical trial of vitamin D analogue becocalcidiol for psoriasis
Read More